Cytokinetics
Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors to treat diseases where muscle performance is compromised. The company develops small-molecule medicines designed to increase muscle function and contractility and pursues muscle-directed investigational therapies for conditions such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy and chronic obstructive pulmonary disease.
Top Stages
3 past transactions
Imbria Pharmaceuticals
Series B in 2025
Imbria Pharmaceuticals, founded in 2018 and headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies targeting cardiometabolic disorders. The company focuses on understanding the underlying mechanisms of these diseases, particularly energetic impairment at the cellular level, to inform its therapeutic candidates. Imbria's pipeline aims to improve the lives of patients suffering from conditions such as non-obstructive hypertrophic cardiomyopathy, stable angina, and heart failure with preserved ejection fraction by restoring or enhancing cellular energy production.
WomenHeart
Grant in 2023
WomenHeart is a non-profit organization serving American women living with or at risk for heart disease.
The Mended Hearts
Grant in 2023
The Mended Hearts Foundation provides support, education, and advocacy for heart disease patients. They provide a patient visiting program, education, support group meetings, and online communities. Their peer support groups help patients and their families understand that there can be a rich, rewarding life after a heart disease diagnosis.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.